BCTX BriaCell Therapeutics Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1610820 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.7%
TTM EPS YoY88.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-203.6%
ROA-154.3%
ROIC (approx.)-408.8%
Asset turnover—
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-07-31 | FY20252025-07-31 | FY20242024-07-31 | FY20232023-07-31 | FY20222022-07-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $29.24M | $21.27M | $27.18M | $15.34M | $8.02M |
| SG&A expense | $6.82M | $5.93M | $6.15M | $7.94M | $7.27M |
| Operating income | -$36.05M | -$27.20M | -$33.33M | -$23.27M | -$15.29M |
| Interest expense | $29,631 | $36,979 | — | — | $979 |
| Pretax income | $35.33M | $26.56M | $4.93M | $20.30M | -$26.84M |
| Net income | -$34.90M | -$26.31M | -$4.79M | -$20.30M | -$26.84M |
| EBITDA | -$35.95M | -$27.11M | -$33.26M | — | -$15.27M |
| EPS (basic) | -6.97 | -62.19 | -43.68 | -1.30 | -1.73 |
| EPS (diluted) | -6.97 | -62.19 | -43.68 | -1.30 | -1.73 |
| Weighted avg. shares (diluted) | 5.01M | 423,114 | 109,699 | 15.62M | 15.49M |
| Balance sheet | |||||
| Cash & equivalents | $9.85M | $10.49M | $862,089 | $21.25M | $41.04M |
| Short-term investments | $10.69M | $7.37M | — | — | — |
| Receivables | — | — | — | $18,873 | $24,103 |
| Current assets | $22.04M | $19.93M | $3.65M | $26.95M | $42.35M |
| PP&E, net | $319,804 | $296,819 | $388,175 | $2,500 | $2,500 |
| Intangibles | $169,254 | $184,525 | $199,796 | $215,068 | $230,339 |
| Total assets | $23.58M | $21.65M | $5.87M | $27.16M | $42.58M |
| Current liabilities | $7.98M | $3.98M | $7.46M | $1.80M | $941,087 |
| Total liabilities | $8.02M | $4.32M | $8.56M | $30.94M | $32.25M |
| Shareholders' equity | $16.40M | $17.88M | -$2.38M | -$3.78M | $10.33M |
| Shares outstanding | 8.71M | 1.88M | 121,907 | 15.98M | 15.52M |
| Cash flow statement | |||||
| Operating cash flow | -$28.65M | -$28.17M | -$24.13M | -$23.74M | -$12.48M |
| Capital expenditure | $127,049 | — | $456,801 | — | — |
| Free cash flow | -$28.78M | — | -$24.58M | — | — |
| Investing cash flow | -$3.81M | -$7.65M | -$681,801 | — | — |
| Financing cash flow | $31.81M | $45.45M | $4.42M | $3.95M | -$3.74M |
| Depreciation & amortization | $104,064 | $91,356 | $68,626 | — | $15,272 |
| Stock-based compensation | $1.13M | $656,829 | $1.80M | $2.19M | $3.07M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.